AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">GeneTx/Ultragenyx</td>
<td>UBE3A</td>
</tr>
<tr>
<td class="label">Roche/Neurocrine</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Vigonvita</td>
<td>CDKL5</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">Takeda/SB</td>
<td>SLC6A1</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>STXBP1</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>GABRB3</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>PCDH19</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>STK-001</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>STK-002</td>
</tr>
<tr>
<td class="label">GeneTx/Ultragenyx</td>
<td>GTX-102</td>
</tr>
<tr>
<td class="label">Roche</td>
<td>—</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Focus</td>
</tr>
<tr>

AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">AAV Gene Therapy for Neurodevelopmental Epilepsy — Competitive Landscape & Delivery Alternatives</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">GeneTx/Ultragenyx</td>
<td>UBE3A</td>
</tr>
<tr>
<td class="label">Roche/Neurocrine</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Vigonvita</td>
<td>CDKL5</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">Takeda/SB</td>
<td>SLC6A1</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>STXBP1</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>GABRB3</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>PCDH19</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>STK-001</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>STK-002</td>
</tr>
<tr>
<td class="label">GeneTx/Ultragenyx</td>
<td>GTX-102</td>
</tr>
<tr>
<td class="label">Roche</td>
<td>—</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Focus</td>
</tr>
<tr>
<td class="label">[Stoke Therapeutics](/companies/stoke-therapeutics) (NASDAQ: STOK)</td>
<td>SCN1A ASO (STK-001/002)</td>
</tr>
<tr>
<td class="label">[Encoded Therapeutics](/companies/encoded-therapeutics) (private)</td>
<td>SCN1A AAV gene activation</td>
</tr>
<tr>
<td class="label">[Ultragenyx](/companies/ultragenyx) (NASDAQ: UGX)</td>
<td>UBE3A ASO (GTX-102)</td>
</tr>
<tr>
<td class="label">Roche/Neurocrine (NASDAQ: NBIX)</td>
<td>SCN1A AAV</td>
</tr>
<tr>
<td class="label">[Vigonvita Sciences](/companies/vigonvita-sciences) (private, China)</td>
<td>CDKL5 AAV</td>
</tr>
<tr>
<td class="label">[GeneTx Biotherapeutics](/companies/genetx-biotherapeutics) (Ultragenyx subsidiary)</td>
<td>UBE3A ASO (GTX-102)</td>
</tr>
<tr>
<td class="label">UC Berkeley (Bhatt group)</td>
<td>SCN1A gene therapy</td>
</tr>
<tr>
<td class="label">Boston Children's (Berry-Kravis)</td>
<td>Multiple NDE</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Lipid nanoparticles (LNPs)</td>
<td>Encapsulate mRNA/DNA in ionizable lipid</td>
</tr>
<tr>
<td class="label">Exosomes/EVs</td>
<td>Cell-derived vesicles with targeting ligands</td>
</tr>
<tr>
<td class="label">Polymer nanoparticles</td>
<td>PLGA/PEI encapsulation</td>
</tr>
<tr>
<td class="label">Cell-penetrating peptides</td>
<td>Peptide-mediated delivery</td>
</tr>
<tr>
<td class="label">Vector</td>
<td>Cargo Capacity</td>
</tr>
<tr>
<td class="label">Lentivirus (LV)</td>
<td>~8kb</td>
</tr>
<tr>
<td class="label">HSV-1 amplicons</td>
<td>~150kb</td>
</tr>
<tr>
<td class="label">Engineered AAV (PHP.eB, AAV.CAP-B10)</td>
<td>~4.7kb</td>
</tr>
<tr>
<td class="label">Anc80L65</td>
<td>~4.7kb</td>
</tr>
<tr>
<td class="label">Technology</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Base editing (in vivo)</td>
<td>Correct point mutations without DSBs</td>
</tr>
<tr>
<td class="label">Prime editing</td>
<td>Insert/delete/replace without DSBs</td>
</tr>
<tr>
<td class="label">RNA editing (ADAR)</td>
<td>Endogenous enzyme redirected via guide RNA</td>
</tr>
<tr>
<td class="label">ASOs (intrathecal)</td>
<td>Splice modulation or knockdown</td>
</tr>
<tr>
<td class="label">CRISPRa/dCas9</td>
<td>Transcriptional activation</td>
</tr>
<tr>
<td class="label">Focused ultrasound + microbubbles</td>
<td>Transient BBB opening for IV vectors</td>
</tr>
<tr>
<td class="label">Convection-enhanced delivery (CED)</td>
<td>Pressure-driven interstitial infusion</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Surface ligand decoration</td>
<td>Angiopep-2, transferrin for BBB crossing</td>
</tr>
<tr>
<td class="label">Ionizable lipid optimization</td>
<td>Enhanced CNS tropism via lipid design</td>
</tr>
<tr>
<td class="label">Focused ultrasound</td>
<td>Temporary BBB opening with microbubbles</td>
</tr>
<tr>
<td class="label">Intraparenchymal injection</td>
<td>Direct brain delivery bypasses BBB</td>
</tr>
<tr>
<td class="label">Intranasal delivery</td>
<td>Olfactory pathway to CNS</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Moderna's CNS LNP platform</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">BioNTech's CNS programs</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Academic collaborations</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Focus</td>
</tr>
<tr>
<td class="label">Codiak BioSciences</td>
<td>Exosome therapeutics</td>
</tr>
<tr>
<td class="label">Evox Therapeutics</td>
<td>Rare disease</td>
</tr>
<tr>
<td class="label">Anjarium Biosciences</td>
<td>CNS</td>
</tr>
<tr>
<td class="label">Capricor Therapeutics</td>
<td>Exosomes for various</td>
</tr>
<tr>
<td class="label">AgeX Therapeutics</td>
<td>Cell-derived EVs</td>
</tr>
<tr>
<td class="label">Company/Group</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Beam Therapeutics</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Prime Medicine</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Verve Therapeutics</td>
<td>Clinical (cardiovascular)</td>
</tr>
<tr>
<td class="label">Academic (UC Berkeley)</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Solution Approaches</td>
</tr>
<tr>
<td class="label">Large cargo (Cas9 + gRNA + template)</td>
<td>Split-intein systems, smaller Cas9 variants (SaCas9, CasMINI)</td>
</tr>
<tr>
<td class="label">BBB delivery</td>
<td>ICV, ICM, or focused ultrasound</td>
</tr>
<tr>
<td class="label">Editing efficiency</td>
<td>Optimize promoter, regulatory elements</td>
</tr>
<tr>
<td class="label">Immune response</td>
<td>Self-delivering RNP, lipid encapsulation</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Dravet (missense)</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Angelman</td>
<td>UBE3A</td>
</tr>
<tr>
<td class="label">KCNQ2</td>
<td>KCNQ2</td>
</tr>
<tr>
<td class="label">STXBP1</td>
<td>STXBP1</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Platform</td>
</tr>
<tr>
<td class="label">Beam Therapeutics</td>
<td>Base editing</td>
</tr>
<tr>
<td class="label">Prime Medicine</td>
<td>Prime editing</td>
</tr>
<tr>
<td class="label">Verve Therapeutics</td>
<td>Base editing</td>
</tr>
<tr>
<td class="label">CRISPR Therapeutics</td>
<td>CRISPR-Cas9</td>
</tr>
<tr>
<td class="label">Intellia Therapeutics</td>
<td>LNP CRISPR</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Redosability</td>
<td>Can repeat dosing without immune concerns</td>
</tr>
<tr>
<td class="label">Transient effect</td>
<td>Allows titration of expression levels</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>No genomic integration, reversible</td>
</tr>
<tr>
<td class="label">Variant flexibility</td>
<td>Can address many mutation types with same platform</td>
</tr>
<tr>
<td class="label">Timing control</td>
<td>Expression can be modulated by dosing schedule</td>
</tr>
<tr>
<td class="label">No packaging limits</td>
<td>Can deliver full-length transcripts</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Current Approaches</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Expression typically 1-2 weeks; may require repeat dosing</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Brain delivery remains difficult; similar BBB challenges to other modalities</td>
</tr>
<tr>
<td class="label">Efficiency</td>
<td>Editing efficiency varies by tissue and cell type</td>
</tr>
<tr>
<td class="label">Specificity</td>
<td>Off-target editing in non-target tissues possible</td>
</tr>
<tr>
<td class="label">Validation</td>
<td>Less clinical validation than ASOs or AAV</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Platform</td>
</tr>
<tr>
<td class="label">ProMis Neuroscience</td>
<td>ADAR</td>
</tr>
<tr>
<td class="label">Shape Therapeutics</td>
<td>RNA editing</td>
</tr>
<tr>
<td class="label">Rewind Therapeutics</td>
<td>ADAR</td>
</tr>
<tr>
<td class="label">Korro Bio</td>
<td>ADAR</td>
</tr>
<tr>
<td class="label">Hapa Therapeutics</td>
<td>RNA editing</td>
</tr>
<tr>
<td class="label">Ascidian Therapeutics</td>
<td>RNA editing</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>ASO</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>Weeks-months</td>
</tr>
<tr>
<td class="label">Redosability</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Clinical validation</td>
<td>High (Spinal Muscular Atrophy)</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Intrathecal</td>
</tr>
<tr>
<td class="label">Gene size limits</td>
<td>None</td>
</tr>
<tr>
<td class="label">Off-target risk</td>
<td>Splice off-target</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Non-invasive</td>
<td>Avoids surgical injection (ICV/ICM), reduces surgical risks</td>
</tr>
<tr>
<td class="label">Repeatable</td>
<td>Can perform multiple treatment sessions if needed</td>
</tr>
<tr>
<td class="label">Targeted</td>
<td>Can focus on specific brain regions (e.g., hippocampus, cortex)</td>
</tr>
<tr>
<td class="label">Scalable</td>
<td>Can treat multiple brain regions in one session</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Works with any IV-delivered therapeutic (AAV, LNP, ASO, small molecules)</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Range</td>
</tr>
<tr>
<td class="label">Ultrasound frequency</td>
<td>0.2-1 MHz</td>
</tr>
<tr>
<td class="label">Pressure threshold</td>
<td>0.3-0.6 MPa</td>
</tr>
<tr>
<td class="label">Pulse duration</td>
<td>10-30 ms</td>
</tr>
<tr>
<td class="label">Treatment duration</td>
<td>1-2 minutes per target</td>
</tr>
<tr>
<td class="label">Opening duration</td>
<td>4-6 hours</td>
</tr>
<tr>
<td class="label">Company/Institution</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">CarThera</td>
<td>Glioblastoma</td>
</tr>
<tr>
<td class="label">Insightec</td>
<td>Tremor (Parkinson's)</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>Alzheimer's</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>NDE</td>
</tr>
<tr>
<td class="label">Gene Therapy</td>
<td>FUS Application</td>
</tr>
<tr>
<td class="label">AAV9-IV</td>
<td>FUS to cortex</td>
</tr>
<tr>
<td class="label">LNP-mRNA</td>
<td>FUS for BBB opening</td>
</tr>
<tr>
<td class="label">ASO</td>
<td>FUS enhancement</td>
</tr>
<tr>
<td class="label">Base editor</td>
<td>FUS delivery</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">BBB bypass</td>
<td>Direct delivery to brain, no need for BBB-crossing vectors</td>
</tr>
<tr>
<td class="label">Large distribution</td>
<td>Can cover whole brain regions (hemispheres, cerebellum)</td>
</tr>
<tr>
<td class="label">No systemic exposure</td>
<td>Minimal off-target effects, lower immunogenicity</td>
</tr>
<tr>
<td class="label">Dose control</td>
<td>Adjustable infusion rates, can target specific regions</td>
</tr>
<tr>
<td class="label">Gene-size independent</td>
<td>Can deliver any size payload (AAV, LV, HSV-1)</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Range</td>
</tr>
<tr>
<td class="label">Infusion rate</td>
<td>0.5-10 μL/min</td>
</tr>
<tr>
<td class="label">Catheter design</td>
<td>Single or multiple</td>
</tr>
<tr>
<td class="label">Distribution volume</td>
<td>1-10 cm per infusion</td>
</tr>
<tr>
<td class="label">Reflux prevention</td>
<td>Critical</td>
</tr>
<tr>
<td class="label">Real-time imaging</td>
<td>MRI with gadolinium</td>
</tr>
<tr>
<td class="label">Indication</td>
<td>Therapeutic</td>
</tr>
<tr>
<td class="label">Parkinson's</td>
<td>GDNF, AAV-AADC</td>
</tr>
<tr>
<td class="label">Diffuse intrinsic pontine glioma (DIPG)</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td class="label">Brain tumors</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Rare CNS disorders</td>
<td>Various</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>CED</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>Bulk flow (cm scale)</td>
</tr>
<tr>
<td class="label">Coverage</td>
<td>Can cover entire hemisphere</td>
</tr>
<tr>
<td class="label">Invasiveness</td>
<td>Requires surgery</td>
</tr>
<tr>
<td class="label">Precision</td>
<td>Targeted to specific regions</td>
</tr>
<tr>
<td class="label">Reversibility</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Re-dosing</td>
<td>Possible with new catheters</td>
</tr>
<tr>
<td class="label">Company/Institution</td>
<td>Focus</td>
</tr>
<tr>
<td class="label">BrainCyte (formerly SureGene)</td>
<td>CNS gene therapy via CED</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>Parkinson's (AAV-AADC)</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>Brain tumor delivery</td>
</tr>
<tr>
<td class="label">Syner-G</td>
<td>CED catheter technology</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Example</td>
</tr>
<tr>
<td class="label">Sodium channel blockers</td>
<td>Fenfluramine (FDA-approved 2020)</td>
</tr>
<tr>
<td class="label">CBD</td>
<td>Epidiolex (FDA-approved 2018)</td>
</tr>
<tr>
<td class="label">VNS therapy</td>
<td>Pacemaker-like device</td>
</tr>
<tr>
<td class="label">ASO</td>
<td>STK-001 (Stoke)</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-SCN1A (Encoded)</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Modality</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>ASO</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>AAV-CRISPRa</td>
</tr>
<tr>
<td class="label">Roche/Neurocrine</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">UC Berkeley (Bhatt)</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Academic (CHOP)</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Academic (UCSF)</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Modality</td>
</tr>
<tr>
<td class="label">GeneTx/Ultragenyx</td>
<td>ASO (GTX-102)</td>
</tr>
<tr>
<td class="label">Roche</td>
<td>ASO</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Academia (multiple groups)</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Roche</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Various biotech</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Takeda/SBI</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Academia (multiple groups)</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Various biotech</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Entity</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Academia (multiple groups)</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Various biotech</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Event</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>Series C</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>IPO (NASDAQ)</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>Follow-on</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>Follow-on</td>
</tr>
<tr>
<td class="label">Ultragenyx (GeneTx)</td>
<td>Acquisition</td>
</tr>
<tr>
<td class="label">Roche/Neurocrine</td>
<td>Partnership</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>Series B</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>Series A</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>Series D</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Market Cap</td>
</tr>
<tr>
<td class="label">[Stoke Therapeutics](/companies/stoke-therapeutics) (STOK)</td>
<td>~$800M-1B</td>
</tr>
<tr>
<td class="label">[Ultragenyx](/companies/ultragenyx) (UGX)</td>
<td>~$2-3B</td>
</tr>
<tr>
<td class="label">Ionis Pharmaceuticals</td>
<td>~$5B</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Dravet (SCN1A)</td>
</tr>
<tr>
<td class="label">Target validity</td>
<td>High — causal gene</td>
</tr>
<tr>
<td class="label">Technical risk</td>
<td>Moderate — packaging</td>
</tr>
<tr>
<td class="label">Regulatory path</td>
<td>Clear (FDA orphan)</td>
</tr>
<tr>
<td class="label">Commercial opportunity</td>
<td>$1B+ (rare disease, high unmet need)</td>
</tr>
<tr>
<td class="label">Competition</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Regulatory Strategy</td>
</tr>
<tr>
<td class="label">Long-term follow-up requirements</td>
<td>Post-marketing commitments, disease registries</td>
</tr>
<tr>
<td class="label">Pediatric population</td>
<td>Clear juvenile toxicology packages, age-appropriate endpoints</td>
</tr>
<tr>
<td class="label">Valid biomarker development</td>
<td>Qualification through FDA's biomarker qualification program</td>
</tr>
<tr>
<td class="label">Single-arm trial design</td>
<td>Natural history as comparator, historical controls</td>
</tr>
<tr>
<td class="label">Combination products</td>
<td>Center for Drug Evaluation and Research (CDER) + Center for Biologics Evaluation and Research (CBER) coordination</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Pathway</td>
</tr>
<tr>
<td class="label">EU (EMA)</td>
<td>PRIME designation, Adaptive Pathways</td>
</tr>
<tr>
<td class="label">UK (MHRA)</td>
<td>ILAP designation</td>
</tr>
<tr>
<td class="label">Japan (PMDA)</td>
<td>Sakigake designation</td>
</tr>
<tr>
<td class="label">Australia (TGA)</td>
<td>Priority determination</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Implementation</td>
</tr>
<tr>
<td class="label">Long-term follow-up</td>
<td>15-year follow-up per FDA guidance for AAV</td>
</tr>
<tr>
<td class="label">Pharmacovigilance</td>
<td>Active surveillance via registries</td>
</tr>
<tr>
<td class="label">Real-time safety</td>
<td>Integration with FDA Sentinel System</td>
</tr>
<tr>
<td class="label"> immunogenicity monitoring</td>
<td>Anti-AAV antibody titers, T-cell responses</td>
</tr>
<tr>
<td class="label">Research Group</td>
<td>Institution</td>
</tr>
<tr>
<td class="label">Dr. Eric Marsh</td>
<td>CHOP</td>
</tr>
<tr>
<td class="label">Dr. Scott J. Golde</td>
<td>UC Davis</td>
</tr>
<tr>
<td class="label">Research Group</td>
<td>Institution</td>
</tr>
<tr>
<td class="label">Vigonvita Therapeutics</td>
<td>Industry</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Institution/Company</td>
</tr>
<tr>
<td class="label">AAV-SCN1A</td>
<td>Roche/Neurocrine</td>
</tr>
<tr>
<td class="label">Mini-SCN1A</td>
<td>UC Berkeley (Bhatt)</td>
</tr>
<tr>
<td class="label">CRISPRa-SCN1A</td>
<td>Encoded Therapeutics</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Institution/Company</td>
</tr>
<tr>
<td class="label">GTX-102</td>
<td>GeneTx/Ultragenyx</td>
</tr>
<tr>
<td class="label">AAV-UBE3A</td>
<td>Various academic</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Institution/Company</td>
</tr>
<tr>
<td class="label">AAV-KCNQ2</td>
<td>CHOP</td>
</tr>
<tr>
<td class="label">AAV-KCNQ2</td>
<td>UC Davis</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Institution/Company</td>
</tr>
<tr>
<td class="label">AAV-CDKL5</td>
<td>Vigonvita</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Institution/Company</td>
</tr>
<tr>
<td class="label">AAV-STXBP1</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Institution/Company</td>
</tr>
<tr>
<td class="label">AAV-GABRB3</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Institution/Company</td>
</tr>
<tr>
<td class="label">AAV-PCDH19</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Platform</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Triple transfection (HEK293)</td>
<td>Flexible serotype, high titer</td>
</tr>
<tr>
<td class="label">Baculovirus/Sf9</td>
<td>High yield, large scale</td>
</tr>
<tr>
<td class="label">Stable producer cell line</td>
<td>Consistent, lower cost</td>
</tr>
<tr>
<td class="label">Suspension culture</td>
<td>Scalable, lower cost</td>
</tr>
<tr>
<td class="label">Cost Component</td>
<td>Typical Range</td>
</tr>
<tr>
<td class="label">GMP manufacturing</td>
<td>$500K-2M per batch</td>
</tr>
<tr>
<td class="label">Fill-finish</td>
<td>$100K-300K per batch</td>
</tr>
<tr>
<td class="label">Quality control</td>
<td>$200K-500K per batch</td>
</tr>
<tr>
<td class="label">Total per dose</td>
<td>$1M-5M</td>
</tr>
<tr>
<td class="label">Organization</td>
<td>Focus</td>
</tr>
<tr>
<td class="label">[Dravet Syndrome Foundation](/organizations/dravet-syndrome-foundation)</td>
<td>Dravet</td>
</tr>
<tr>
<td class="label">[Angelman Syndrome Foundation](/organizations/angelman-syndrome-foundation)</td>
<td>Angelman</td>
</tr>
<tr>
<td class="label">[Cute Syndrome Foundation](/organizations/cute-syndrome-foundation)</td>
<td>CDKL5</td>
</tr>
<tr>
<td class="label">[Ring14 USA](/organizations/ring14-usa)</td>
<td>Ring14 chromosome</td>
</tr>
<tr>
<td class="label">[SLC6A1 Connect](/organizations/slc6a1-connect)</td>
<td>SLC6A1</td>
</tr>
<tr>
<td class="label">[STXBP1 Foundation](/organizations/stxbp1-foundation)</td>
<td>STXBP1</td>
</tr>
<tr>
<td class="label">[PCDH19 Alliance](/organizations/pcdh19-alliance)</td>
<td>PCDH19</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Study</td>
</tr>
<tr>
<td class="label">Dravet</td>
<td>RDCRN DM1B</td>
</tr>
<tr>
<td class="label">Angelman</td>
<td>N=400 registry</td>
</tr>
<tr>
<td class="label">CDKL5</td>
<td>RDCRN DM1B</td>
</tr>
<tr>
<td class="label">KCNQ2</td>
<td>RDCRN</td>
</tr>
<tr>
<td class="label">STXBP1</td>
<td>STXBP1 Registry</td>
</tr>
<tr>
<td class="label">PCDH19</td>
<td>PCDH19 Registry</td>
</tr>
<tr>
<td class="label">SLC6A1</td>
<td>SLC6A1 Registry</td>
</tr>
<tr>
<td class="label">Ring14</td>
<td>Ring14 Registry</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Non-invasive</td>
<td>No surgery, reduces procedural risks in pediatric patients</td>
</tr>
<tr>
<td class="label">Repeatable</td>
<td>Can re-dose if needed without surgical concerns</td>
</tr>
<tr>
<td class="label">Lower systemic exposure</td>
<td>Reduced off-target effects and immunogenicity</td>
</tr>
<tr>
<td class="label">Early intervention</td>
<td>Potential for treatment in infancy without major surgery</td>
</tr>
<tr>
<td class="label">Cost-effective</td>
<td>Simpler administration than ICV/ICM</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Notes</td>
</tr>
<tr>
<td class="label">Particle size</td>
<td>Optimal: 10-100nm; larger particles trapped in nasal cavity</td>
</tr>
<tr>
<td class="label">Surface charge</td>
<td>Neutral to slightly positive enhances absorption</td>
</tr>
<tr>
<td class="label">Mucoadhesive agents</td>
<td>Chitosan, poloxamer for enhanced retention</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Must protect vector from nasal enzymes and pH</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Impact</td>
</tr>
<tr>
<td class="label">Vector type</td>
<td>AAV less efficient than smaller particles</td>
</tr>
<tr>
<td class="label">Age</td>
<td>Young mice show higher transduction than adults</td>
</tr>
<tr>
<td class="label">Volume</td>
<td>Smaller volumes (20-50μL) better than larger</td>
</tr>
<tr>
<td class="label">Timing</td>
<td>Fasting state improves absorption</td>
</tr>
<tr>
<td class="label">Company/Institution</td>
<td>Focus</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>AAV nasal delivery for CNS</td>
</tr>
<tr>
<td class="label">Kurve Therapeutics</td>
<td>Intranasal platform</td>
</tr>
<tr>
<td class="label">neuronasal</td>
<td>Non-invasive CNS delivery</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Intranasal</td>
</tr>
<tr>
<td class="label">Invasiveness</td>
<td>None</td>
</tr>
<tr>
<td class="label">BBB bypass</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Coverage</td>
<td>Limited (olfactory)</td>
</tr>
<tr>
<td class="label">Repeatable</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Pediatric suitable</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Technical complexity</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">SCN1A variant type</td>
<td>Dravet</td>
</tr>
<tr>
<td class="label">UBE3A mutation type</td>
<td>Angelman</td>
</tr>
<tr>
<td class="label">KCNQ2 variant classification</td>
<td>KCNQ2-E</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Detection Method</td>
</tr>
<tr>
<td class="label">Nav1.1 protein expression</td>
<td>IHC/Western blot</td>
</tr>
<tr>
<td class="label">SCN1A mRNA levels</td>
<td>qPCR</td>
</tr>
<tr>
<td class="label">UBE3A expression</td>
<td>IHC</td>
</tr>
<tr>
<td class="label">Kv7.2 channel function</td>
<td>Electrophysiology</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Target</td>
</tr>
<tr>
<td class="label">SCN1A expression</td>
<td>Nav1.1 protein</td>
</tr>
<tr>
<td class="label">Neurofilament light (NfL)</td>
<td>Axonal injury</td>
</tr>
<tr>
<td class="label">Tau/phospho-tau</td>
<td>Tau pathology</td>
</tr>
<tr>
<td class="label">YKL-40</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Seizure frequency</td>
<td>Diary + EEG</td>
</tr>
<tr>
<td class="label">EEG normalization</td>
<td>Quantitative EEG</td>
</tr>
<tr>
<td class="label">Background slowing</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Interictal spikes</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Brain volume</td>
<td>MRI</td>
</tr>
<tr>
<td class="label">White matter integrity</td>
<td>DTI</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>FDG-PET</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>TSPO-PET</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Biomarker</td>
</tr>
<tr>
<td class="label">Dose-finding</td>
<td>Expression biomarker</td>
</tr>
<tr>
<td class="label">Patient stratification</td>
<td>Genetic + expression</td>
</tr>
<tr>
<td class="label">Go/No-go decisions</td>
<td>Early expression changes</td>
</tr>
<tr>
<td class="label">Accelerated approval</td>
<td>Surrogate endpoint</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Program</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>STK-001</td>
</tr>
<tr>
<td class="label">GeneTx/Ultragenyx</td>
<td>GTX-102</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>ETX101</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Definition</td>
</tr>
<tr>
<td class="label">Seizure frequency</td>
<td>% change from baseline</td>
</tr>
<tr>
<td class="label">Seizure freedom</td>
<td>Zero seizures in period</td>
</tr>
<tr>
<td class="label">Response rate</td>
<td>≥50% reduction</td>
</tr>
<tr>
<td class="label">Status epilepticus frequency</td>
<td>Number of SE events</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Instrument</td>
</tr>
<tr>
<td class="label">Cognitive function</td>
<td>Bayley-3, BSID-III</td>
</tr>
<tr>
<td class="label">Adaptive behavior</td>
<td>Vineland-3</td>
</tr>
<tr>
<td class="label">Motor function</td>
<td>Peabody, GMFM</td>
</tr>
<tr>
<td class="label">Communication</td>
<td>Mullen, ADOS</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Description</td>
</tr>
<tr>
<td class="label">PedsQL</td>
<td>Quality of life</td>
</tr>
<tr>
<td class="label">EQ-5D-Y</td>
<td>Utility measure</td>
</tr>
<tr>
<td class="label">Caregiver burden</td>
<td>Zarit scale</td>
</tr>
<tr>
<td class="label">CGI-C/I</td>
<td>Global impression</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Method</td>
</tr>
<tr>
<td class="label">EEG normalization</td>
<td>Quantitative EEG</td>
</tr>
<tr>
<td class="label">Background improvement</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Interictal epileptiform</td>
<td>EEG</td>
</tr>
<tr>
<td class="label">Seizure burden on EEG</td>
<td>Long-term monitoring</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Endpoint</td>
</tr>
<tr>
<td class="label">Primary</td>
<td>Seizure frequency reduction</td>
</tr>
<tr>
<td class="label">Secondary</td>
<td>CGI-C, Vineland-3</td>
</tr>
<tr>
<td class="label">Exploratory</td>
<td>EEG normalization, NfL</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Endpoint</td>
</tr>
<tr>
<td class="label">Primary</td>
<td>Bayley-3 cognitive score</td>
</tr>
<tr>
<td class="label">Secondary</td>
<td>EEG normalization</td>
</tr>
<tr>
<td class="label">Exploratory</td>
<td>ABC-C, UBE3A expression</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Endpoint</td>
</tr>
<tr>
<td class="label">Primary</td>
<td>Seizure frequency</td>
</tr>
<tr>
<td class="label">Secondary</td>
<td>Developmental assessment</td>
</tr>
<tr>
<td class="label">Exploratory</td>
<td>EEG background</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">Epidiolex (CBD)</td>
<td>Dravet, LGS</td>
</tr>
<tr>
<td class="label">Fenfluramine</td>
<td>Dravet</td>
</tr>
<tr>
<td class="label">Spinraza (ASO)</td>
<td>SMA</td>
</tr>
<tr>
<td class="label">Zolgensma (AAV)</td>
<td>SMA</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Measurement</td>
</tr>
<tr>
<td class="label">Seizure reduction</td>
<td>% responder rate, seizure freedom</td>
</tr>
<tr>
<td class="label">Developmental preservation</td>
<td>IQ/DQ maintenance, milestone achievement</td>
</tr>
<tr>
<td class="label">Mortality reduction</td>
<td>SUDEP prevention</td>
</tr>
<tr>
<td class="label">Caregiver burden</td>
<td>Time savings, QoL</td>
</tr>
<tr>
<td class="label">Long-term disease modification</td>
<td>Reduced progression</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Zolgensma</td>
<td>SMA</td>
</tr>
<tr>
<td class="label">Luxturna</td>
<td>LCA</td>
</tr>
<tr>
<td class="label">HemgenA</td>
<td>Hemophilia</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Genomic integration</td>
<td>AAV can integrate into host genome, potentially disrupting genes</td>
</tr>
<tr>
<td class="label">Off-target tissue expression</td>
<td>Expression in non-target organs (liver, heart)</td>
</tr>
<tr>
<td class="label">Immunogenicity</td>
<td>Immune response to vector capsid or transgene</td>
</tr>
<tr>
<td class="label">Insertional mutagenesis</td>
<td>Theoretical cancer risk from integration</td>
</tr>
<tr>
<td class="label">Germline transmission</td>
<td>Vector DNA in reproductive tissues</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Specific Concerns</td>
</tr>
<tr>
<td class="label">SCN1A</td>
<td>Altered sodium channel function, potential for gain-of-function</td>
</tr>
<tr>
<td class="label">KCNQ2</td>
<td>Channel overexpression, cardiac effects</td>
</tr>
<tr>
<td class="label">CDKL5</td>
<td>Cell cycle effects, potential for tumorigenicity</td>
</tr>
<tr>
<td class="label">UBE3A</td>
<td>Altered ubiquitin pathway</td>
</tr>
<tr>
<td class="label">STXBP1</td>
<td>Synaptic function alterations</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Specific Risks</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>CSF leak, meningitis, spinal cord injury</td>
</tr>
<tr>
<td class="label">ICV/ICM</td>
<td>Intracranial hemorrhage, CNS infection</td>
</tr>
<tr>
<td class="label">IV + FUS</td>
<td>BBB disruption-associated edema</td>
</tr>
<tr>
<td class="label">Systemic</td>
<td>Liver toxicity, complement activation</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Key Assessments</td>
</tr>
<tr>
<td class="label">Day 0-7 (acute)</td>
<td>Immediate adverse events, CRS monitoring</td>
</tr>
<tr>
<td class="label">Week 1-4</td>
<td>Laboratory parameters, liver function</td>
</tr>
<tr>
<td class="label">Month 1-3</td>
<td>Neuroimaging, antibody titers</td>
</tr>
<tr>
<td class="label">Month 6-12</td>
<td>Developmental assessments, seizure frequency</td>
</tr>
<tr>
<td class="label">Year 1-5</td>
<td>Annual comprehensive evaluation</td>
</tr>
<tr>
<td class="label">Year 5-15</td>
<td>Long-term developmental, oncogenic monitoring</td>
</tr>
<tr>
<td class="label">Year 15+</td>
<td>Continued surveillance, reproductive health</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>Events</td>
</tr>
<tr>
<td class="label">Very common (>10%)</td>
<td>Headache, nausea, pyrexia, CSF pleocytosis</td>
</tr>
<tr>
<td class="label">Common (1-10%)</td>
<td>Elevated liver enzymes, mild CRS, injection site reactions</td>
</tr>
<tr>
<td class="label">Uncommon (0.1-1%)</td>
<td>Severe CRS, hepatic dysfunction, neurological symptoms</td>
</tr>
<tr>
<td class="label">Rare (<0.1%)</td>
<td>Insertional mutagenesis, severe neurotoxicity</td>
</tr>
<tr>
<td class="label">Regulatory Body</td>
<td>Key Requirements</td>
</tr>
<tr>
<td class="label">FDA</td>
<td>15-year follow-up, annual BLA updates, REMS program</td>
</tr>
<tr>
<td class="label">EMA</td>
<td>PAES (Post-Authorization Efficacy Studies), risk management plan</td>
</tr>
<tr>
<td class="label">PMDA</td>
<td>Comparable to FDA/EMA, additional post-marketing surveillance</td>
</tr>
<tr>
<td class="label">Health Canada</td>
<td>Similar requirements, mandatory registry participation</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Measures</td>
</tr>
<tr>
<td class="label">Seizure control</td>
<td>Seizure frequency, responder rate, seizure freedom</td>
</tr>
<tr>
<td class="label">Neurodevelopment</td>
<td>IQ/DQ, adaptive behavior, language</td>
</tr>
<tr>
<td class="label">Quality of life</td>
<td>PedsQL, caregiver burden</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>AEs, SAEs, laboratory parameters</td>
</tr>
<tr>
<td class="label">Mortality</td>
<td>All-cause mortality, SUDEP</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Estimated Annual Cost per Patient</td>
</tr>
<tr>
<td class="label">Registry management</td>
<td>$5,000-10,000</td>
</tr>
<tr>
<td class="label">Annual assessments</td>
<td>$3,000-5,000</td>
</tr>
<tr>
<td class="label">Laboratory monitoring</td>
<td>$1,000-2,000</td>
</tr>
<tr>
<td class="label">Data analysis/reporting</td>
<td>$2,000-3,000</td>
</tr>
<tr>
<td class="label">Total</td>
<td>$11,000-20,000/year</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Program</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>STK-001</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>ETX101</td>
</tr>
<tr>
<td class="label">GeneTx/Ultragenyx</td>
<td>GTX-102</td>
</tr>
<tr>
<td class="label">Roche/Neurocrine</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Vigonvita</td>
<td>CDKL5</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Consideration</td>
</tr>
<tr>
<td class="label">Brain volume</td>
<td>~35% of adult at birth</td>
</tr>
<tr>
<td class="label">BBB maturity</td>
<td>More permeable in neonates</td>
</tr>
<tr>
<td class="label">CSF volume</td>
<td>~50% adult volume</td>
</tr>
<tr>
<td class="label">Immune status</td>
<td>Naive to most pathogens</td>
</tr>
<tr>
<td class="label">Age Group</td>
<td>Typical Dose Range (AAV9)</td>
</tr>
<tr>
<td class="label"><6 months</td>
<td>1-2 × 10¹⁴ GC/kg</td>
</tr>
<tr>
<td class="label">6-12 months</td>
<td>1-1.5 × 10¹⁴ GC/kg</td>
</tr>
<tr>
<td class="label">1-5 years</td>
<td>0.8-1.2 × 10¹⁴ GC/kg</td>
</tr>
<tr>
<td class="label">>5 years</td>
<td>Similar to adult</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Dose Adjustment Factor</td>
</tr>
<tr>
<td class="label">ICV/ICM</td>
<td>0.5-0.7× systemic</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>0.7-0.8× systemic</td>
</tr>
<tr>
<td class="label">IV</td>
<td>Standard weight-based</td>
</tr>
<tr>
<td class="label">Program</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Zolgensma (onasemnogene)</td>
<td>SMN1</td>
</tr>
<tr>
<td class="label">Luxturna (voretigene)</td>
<td>RPE65</td>
</tr>
<tr>
<td class="label">Strimvelis (ADA-SCID)</td>
<td>ADA</td>
</tr>
<tr>
<td class="label">Device</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Embrace2</td>
<td>Empatica</td>
</tr>
<tr>
<td class="label">EpiMonitor</td>
<td>Cerebrel</td>
</tr>
<tr>
<td class="label">SAMi</td>
<td>Neuroview</td>
</tr>
<tr>
<td class="label">UNEEG</td>
<td>UNEEG Medical</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Biomarker</td>
</tr>
<tr>
<td class="label">Seizure</td>
<td>Event frequency, duration</td>
</tr>
<tr>
<td class="label">Motor</td>
<td>Gait analysis, ataxia</td>
</tr>
<tr>
<td class="label">Development</td>
<td>Movement quality</td>
</tr>
<tr>
<td class="label">Sleep</td>
<td>Sleep architecture</td>
</tr>
<tr>
<td class="label">Cognition</td>
<td>Attention, response time</td>
</tr>
<tr>
<td class="label">Timepoint</td>
<td>Digital Assessments</td>
</tr>
<tr>
<td class="label">Month 1-3</td>
<td>Weekly seizure diary review</td>
</tr>
<tr>
<td class="label">Month 3-6</td>
<td>Continuous wearable monitoring</td>
</tr>
<tr>
<td class="label">Month 6-12</td>
<td>Quarterly comprehensive</td>
</tr>
<tr>
<td class="label">Year 1-5</td>
<td>Annual + event-driven</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Program</td>
</tr>
<tr>
<td class="label">Stoke Therapeutics</td>
<td>STK-001</td>
</tr>
<tr>
<td class="label">Encoded Therapeutics</td>
<td>ETX101</td>
</tr>
<tr>
<td class="label">Roche/Neurocrine</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Various academic</td>
<td>Natural history studies</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Timeline</td>
</tr>
<tr>
<td class="label">Standard BLA</td>
<td>10-12 months</td>
</tr>
<tr>
<td class="label">Accelerated Approval</td>
<td>6-8 months</td>
</tr>
<tr>
<td class="label">Priority Review</td>
<td>6 months</td>
</tr>
<tr>
<td class="label">Breakthrough Therapy</td>
<td>Rolling review</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Timeline</td>
</tr>
<tr>
<td class="label">Standard MAA</td>
<td>12-18 months</td>
</tr>
<tr>
<td class="label">Conditional Approval</td>
<td>6-9 months</td>
</tr>
<tr>
<td class="label">PRIME</td>
<td>Accelerated</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Pricing Model</td>
</tr>
<tr>
<td class="label">US</td>
<td>Value-based, indications-based</td>
</tr>
<tr>
<td class="label">Germany</td>
<td>Reference pricing, AMNOG</td>
</tr>
<tr>
<td class="label">UK</td>
<td>NICE evaluation</td>
</tr>
<tr>
<td class="label">Japan</td>
<td>National health insurance</td>
</tr>
<tr>
<td class="label">Model Type</td>
<td>Applications</td>
</tr>
<tr>
<td class="label">Knockout (KO)</td>
<td>Gene function, seizure phenotyping</td>
</tr>
<tr>
<td class="label">Knock-in (KI)</td>
<td>Disease-causing variants</td>
</tr>
<tr>
<td class="label">Humanized</td>
<td>Human gene expression</td>
</tr>
<tr>
<td class="label">Application</td>
<td>Utility</td>
</tr>
<tr>
<td class="label">Disease modeling</td>
<td>Patient-derived neurons show disease phenotypes</td>
</tr>
<tr>
<td class="label">Drug screening</td>
<td>Test therapeutic candidates in human cells</td>
</tr>
<tr>
<td class="label">Mechanism studies</td>
<td>Understand pathophysiology</td>
</tr>
<tr>
<td class="label">Toxicity screening</td>
<td>Assess off-target effects</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Pig</td>
<td>Brain size similar to human, gyrencephalic</td>
</tr>
<tr>
<td class="label">NHP</td>
<td>Closest to human CNS, immune relevance</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">Dravet Syndrome Natural History</td>
<td>RDCRN DM1B</td>
</tr>
<tr>
<td class="label">Genesis Dravet</td>
<td>Taysha/UCB</td>
</tr>
<tr>
<td class="label">FRaISE</td>
<td>French consortium</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">Angelman Registry</td>
<td>Angelman Foundation</td>
</tr>
<tr>
<td class="label">AS Natural History</td>
<td>ASF/NIH</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">CDKL5 Natural History</td>
<td>RDCRN DM1B</td>
</tr>
<tr>
<td class="label">Loulou Foundation</td>
<td>Industry consortium</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">KCNQ2 Natural History</td>
<td>RDCRN</td>
</tr>
<tr>
<td class="label">KCNQ2 Registry</td>
<td>Academic consortium</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Fenfluramine</td>
<td>Dravet</td>
</tr>
<tr>
<td class="label">CBD (Epidiolex)</td>
<td>Dravet, LGS</td>
</tr>
<tr>
<td class="label">Clobazam</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Valproic acid</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Stiripentol</td>
<td>Dravet</td>
</tr>
<tr>
<td class="label">Levetiracetam</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Perampanel</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">Gene Therapy Type</td>
<td>ASM Concern</td>
</tr>
<tr>
<td class="label">AAV-ASMs</td>
<td>None known</td>
</tr>
<tr>
<td class="label">ASO-ASMs</td>
<td>Potential synergism</td>
</tr>
<tr>
<td class="label">CRISPRa-ASMs</td>
<td>None known</td>
</tr>
<tr>
<td class="label">Age Group</td>
<td>ASM Approach</td>
</tr>
<tr>
<td class="label">Neonates (<1mo)</td>
<td>Limited ASM options</td>
</tr>
<tr>
<td class="label">Infants (1-12mo)</td>
<td>Fenfluramine + CBD</td>
</tr>
<tr>
<td class="label">toddlers (1-3yr)</td>
<td>Standard ASMs</td>
</tr>
<tr>
<td class="label">Children (3-12yr)</td>
<td>Full ASM range</td>
</tr>
<tr>
<td class="label">Adolescents</td>
<td>Adult regimens</td>
</tr>
</table>

Overview

Neurodevelopmental epilepsies (NDEs) — including Dravet syndrome (SCN1A), KCNQ2 encephalopathy, CDKL5 deficiency disorder, Angelman syndrome (UBE3A), and others — represent a compelling frontier for gene therapy. These are monogenic disorders with well-defined genetic targets, early onset (enabling intervention before irreversible damage), and profound unmet need (>30% of patients are drug-resistant).

This page maps the competitive landscape of AAV-based approaches and evaluates alternative delivery technologies that could deliver genetic payloads more effectively, safely, or broadly.

Gene Therapy Approach

Competitive Landscape — AAV Gene Therapy Programs

Active Clinical Programs (March 2026)

Clinical-Stage ASO Programs (Non-AAV) (March 2026)

Key Technical Challenges

• Dual-vector approaches (split-intein, trans-splicing)
• Mini-gene/truncated constructs
• Regulatory element optimization
• Gene activation (CRISPRa) to boost endogenous expression from wild-type allele

Companies & Academic Groups (March 2026)

Alternative Delivery Platforms

Non-Viral Delivery

Alternative Viral Vectors

Emerging Technologies

Alternative Delivery Platform Deep Dives

Lipid Nanoparticles (LNPs) for CNS Gene Therapy

Overview

Key Advantages for NDE Applications

Technical Challenges for CNS Delivery

CNS-Targeted LNP Approaches

NDE-Specific LNP Programs

Key Publications

Exosomes and Extracellular Vesicles for Gene Therapy

Overview

Advantages for NDE

Challenges and Limitations

Companies and Programs

NDE Applications

• SCN1A mRNA delivery to neurons
• Targeted delivery to GABAergic interneurons
• Combination with CRISPR systems for gene editing

Key Publications

Base and Prime Editing for NDE

Overview

Why Editing May Be Superior to AAV for NDE

Base Editing for SCN1A (Dravet Syndrome)

Target: ~40% of Dravet patients have missense variants that could be corrected Approach: In vivo base editing to correct pathogenic variants

Challenge: Delivering editing machinery (Cas9, guide RNA, template) to neurons

Prime Editing Advantages for NDE

Delivery Challenges for CNS

Pipeline and Timeline

Key Companies in CNS Editing

Key Publications

RNA Editing for NDE

Overview

Key Technologies

1. ADAR-Mediated Editing (A→I)

• Uses endogenous ADAR (Adenosine Deaminases Acting on RNA) enzymes
• Converts adenosine to inosine (read as guanosine by translation machinery)
• Can correct point mutations where A→G correction is needed
• Self-delivering guide RNAs (sdRNAs) can be packaged in various vectors
• Companies: ProMis Neuroscience, Shape Therapeutics, Rewind Therapeutics

• Uses engineered guide RNAs that recruit endogenous ADAR
• No foreign protein delivery required — reduces immunogenicity
• Repeat dosing possible
• Suitable for target validation before committing to DNA editing

• Cas13-based RNA targeting (Cas13a, Cas13b, Cas13d)
• Direct installation of edits rather than recruitment
• Higher efficiency but requires protein delivery

Advantages for NDE

Challenges

NDE-Specific Applications

SCN1A (Dravet Syndrome)

• Many Dravet missense variants could be corrected via A→I editing
• Target: ~40% of patients have missense mutations amenable to ADAR editing
• Companies exploring: ProMis Neuroscience has SCN1A program

• Loss-of-function variants could be corrected
• Channel function restored via RNA editing
• Early research stage

• Could potentially upregulate paternal UBE3A allele
• Approach: targeting UBE3A-ATS to unleash endogenous expression

Companies and Programs

Comparison: RNA Editing vs. Other Modalities

Key Publications

Focused Ultrasound & BBB Opening for Gene Therapy Delivery

Overview

Mechanism

Advantages for NDE Applications

Technical Considerations

Clinical-Stage FUS Programs for CNS Disorders

NDE-Specific Applications

Dravet Syndrome (SCN1A)

• Potential: Enable systemic AAV-SCN1A delivery without ICV/ICM surgery
• Target regions: Cortex, hippocampus (key for seizure foci)
• Challenge: Need to confirm sufficient transduction of GABAergic interneurons

• Potential: Enable systemic delivery of ASO or AAV to achieve paternal allele reactivation
• Target: Whole-brain coverage needed due to diffuse UBE3A expression pattern

• Similar potential as for SCN1A — enable non-invasive delivery
• Need to validate expression levels and distribution

Combined Approaches: FUS + Gene Therapy

Key Publications

Convection-Enhanced Delivery (CED)

Overview

Mechanism

Advantages for NDE Applications

Technical Considerations

Clinical Applications of CED

NDE-Specific Applications

Gene Therapy Delivery via CED

• AAV delivery: Can use any AAV serotype since BBB crossing not required
• Full SCN1A delivery: Can deliver full-length SCN1A without packaging concerns
• Multiple regions: Can target cortex, hippocampus, cerebellum sequentially
• Pediatric considerations: Requires smaller catheters, careful dose selection

Challenges and Limitations

Key Companies and Programs

Key Publications

Disease-Specific Landscape

Dravet Syndrome (SCN1A)

Disease Overview

• Onset: 6-18 months of age, typically triggered by fever or elevated body temperature
• Seizure types: Febrile seizures, myoclonic seizures, focal impaired awareness seizures, tonic-clonic seizures, status epilepticus
• Developmental trajectory: Normal early development followed by plateau then regression (cognitive decline, ataxia, gait abnormalities)
• Comorbidities: Sleep dysfunction, behavioral issues (autism-like features), movement disorders
• Mortality: 15-20% due to SUDEP (Sudden Unexpected Death in Epilepsy) and prolonged seizures

Current Treatment Landscape

Gene Therapy Approaches

1. Stoke Therapeutics — STK-001 (ASO)

• Mechanism: Allele-specific antisense oligonucleotide that reduces expression of mutated allele while allowing wild-type allele to maintain function
• Delivery: Intrathecal ( lumbar puncture into CSF)
• Clinical data: Phase 1/2 (NCT04414332) showing dose-dependent seizure reduction; >50% responders at highest dose
• Advantages: Well-established ASO platform, proven in spinal muscular atrophy
• Challenges: Requires precise allele targeting, repeated dosing may be needed

• Mechanism: AAV9-delivered CRISPR-activator to upregulate wild-type SCN1A allele expression
• Delivery: Intra-cisterna magna (ICM) for direct CNS access
• Status: IND-enabling studies, received $135M Series C (2023)
• Advantages: Single administration potential, targets both alleles (by upregulating WT)
• Challenges: Gene activation efficiency, long-term expression durability

• Challenge: SCN1A coding sequence (~6kb) exceeds AAV capacity (~4.7kb)
• Solutions being explored:
• Dual-AAV with split-intein (nature-inspired protein splicing)
• Truncated/mini-SCN1A with optimized regulatory elements
• Self-complementary AAV for enhanced transduction

Competitive Positioning (March 2026)

Key Publications

KCNQ2 Encephalopathy

Disease Overview

• Onset: Early infancy (first week to months)
• Seizures: Focal seizures, tonic seizures, epileptic spasms
• EEG: Burst-suppression pattern common
• Outcome: Variable — from severe intellectual disability to milder developmental delay
• Prevalence: ~1 in 50,000-100,000

Gene Therapy Considerations

• Gene size: KCNQ2 coding sequence (~1.6kb) fits easily in AAV
• Channel biology: Must restore proper channel function (Kv7.2/7.3 heterotetramers)
• Direction: Loss-of-function requires gene replacement; gain-of-function may need knockdown
• Delivery: Similar challenges to SCN1A — GABAergic neuron targeting critical
• Status: Preclinical — academic groups (UC Davis, Children's Hospital Philadelphia) active

Programs to Track

CDKL5 Deficiency Disorder

Disease Overview

• Onset: Early infancy (3-12 months)
• Seizures: Refractory, multiple types including infantile spasms
• Developmental outcome: Severe intellectual disability, gross motor impairment
• Gene size: CDKL5 coding sequence (~1.5kb) fits well in AAV

Programs

• Vigonvita Therapeutics: AAV-CDKL5 program in preclinical development
• Ultragenyx: Has explored CDKL5 programs (though primary focus on Angelman)
• Academic: Various groups with CDKL5 gene replacement approaches

Angelman Syndrome (UBE3A)

Disease Overview

• Prevalence: 1 in 10,000-20,000
• Core features: Severe intellectual disability, ataxia, happy demeanor, minimal speech, epilepsy (80%)
• Cause: Maternal deletion (70%), paternal uniparental disomy (5-10%), imprinting center defects (3-5%), UBE3A mutations (10-20%)

Gene Therapy Approaches

1. GeneTx/Ultragenyx — GTX-102 (ASO)

• Mechanism: ASO to inhibit UBE3A-ATS (antisense transcript) that silences paternal allele, allowing reactivation
• Delivery: Intravenous (optimized for brain delivery)
• Status: Phase 1/2 (NCT04259281), ages 4-17
• Clinical data: Early data showing EEG improvement and behavioral benefits
• Advantages: Addresses root cause (maternal allele loss), IV delivery
• Challenges: Requires sustained dosing, variable reactivation efficiency

• Challenge: UBE3A is imprinted — delivering a functional gene may not address the imprinting mechanism
• Approach: May need to deliver to specific brain regions (cortex, cerebellum) for maximal effect
• Status: Preclinical — academic and company programs
• Advantage: Single administration potential

• First-generation GTX-102 replaced by next-generation ASOs with improved delivery

Competitive Landscape (March 2026)

Key Publications

STXBP1 Encephalopathy

Disease Overview

• Onset: First year of life (typically 1-12 months)
• Seizures: Multiple types — infantile spasms, focal seizures, tonic-clonic, myoclonic
• EEG: Burst-suppression pattern in many cases
• Outcome: Severe intellectual disability, developmental regression, movement disorders (ataxia, dystonia)
• Prevalence: ~1 in 100,000-150,000, making it one of the more common genetic epileptic encephalopathies

Gene Therapy Considerations

• Gene size: STXBP1 coding sequence (~2kb) fits well within AAV capacity
• Mechanism: Loss-of-function variants require gene replacement to restore normal synaptic function
• Cell targeting: Must deliver to excitatory neurons (glutamatergic) where Munc18-1 function is critical
• Delivery challenge: Broad cortical and cerebellar coverage needed — STXBP1 is expressed throughout the brain

Programs to Track

Research Landscape

• Mechanistic understanding: STXBP1 haploinsufficiency leads to impaired SNARE complex assembly, causing synaptic transmission deficits
• Therapeutic hypothesis: Restoring STXBP1 levels could improve synaptic function and reduce seizure frequency
• Preclinical models: Stxbp1 heterozygous mouse models show spontaneous seizures and cognitive deficits
• See dedicated page: [STXBP1 Encephalopathy — Preclinical Program](/clinical-trials/stxbp1-encephalopathy-preclinical-program)

SLC6A1-Related Epilepsy

Disease Overview

• Onset: Early childhood (1-5 years)
• Seizures: Multiple types — myoclonic-atonic ("drop seizures"), absence, generalized tonic-clonic
• Phenotype: Variable — from mild epilepsy with typical development to severe developmental encephalopathy
• Prevalence: ~1 in 100,000

Gene Therapy Considerations

• Gene size: SLC6A1 coding sequence (~1.5kb) fits well in AAV
• Mechanism: Loss-of-function requires gene replacement to restore GABA reuptake
• Cell targeting: GABAergic interneurons and astrocytic processes
• Advantage: GAT1 is a well-characterized target with clear mechanism

Programs

Competitive Landscape

• Market opportunity: Significant unmet need — 30-40% of patients are refractory to current therapies
• Target validation: Strong genetic evidence — SLC6A1 is a known haploinsufficient cause of epilepsy
• Technical feasibility: Favorable gene size, established AAV delivery to CNS

GABRB3-Related Epilepsy

Disease Overview

• Onset: Early infancy to childhood (6 months to 5 years)
• Seizures: Multiple types — absence seizures, myoclonic, febrile, focal impaired awareness
• Phenotype: Variable — from mild epilepsy with typical development to severe epileptic encephalopathy
• Comorbidities: Autism spectrum disorder (50%+), intellectual disability, behavioral issues
• Prevalence: ~1 in 50,000-100,000

Gene Therapy Considerations

• Gene size: GABRB3 coding sequence (~1.5kb) fits well within AAV capacity
• Mechanism: Loss-of-function variants require gene replacement to restore inhibitory signaling
• Cell targeting: GABAergic interneurons throughout cortex, thalamus, and hippocampus
• Delivery challenge: Broad CNS distribution needed — GABRB3 expressed widely

Programs to Track

Research Landscape

• Mechanistic understanding: GABRB3-containing GABA-A receptors mediate fast inhibitory transmission; loss leads to network hyperexcitability
• Therapeutic hypothesis: Restoring GABRB3 levels could reduce seizure frequency and improve neurodevelopmental outcomes
• Preclinical models: Gabrb3 knockout mice show spontaneous seizures and behavioral deficits
• Key challenge: GABRB3 is part of a larger gene cluster (GABRA5, GABRB3, GABRG3) with imprinting-like regulation — may require careful regulatory element design

PCDH19-Related Epilepsy (EFMR)

Disease Overview

• Onset: 6 months to 5 years of age
• Seizures: Multiple types — focal, generalized, febrile, infantile spasms
• Phenotype: Variable intellectual disability (mild to moderate), autism spectrum features
• Prevalence: One of the most common genetic epilepsies in females (~5-10% of cases)
• Inheritance: X-linked dominant — females heterozygous affected, males typically unaffected carriers

Gene Therapy Considerations

• Gene size: PCDH19 coding sequence (~2.5kb) fits well within AAV capacity
• Mechanism: Loss-of-function requires gene replacement to restore cell adhesion function
• Cell targeting: Excitatory neurons in cortex and limbic structures
• Delivery challenge: Similar to other NDEs — broad CNS coverage needed

Programs to Track

Research Landscape

• Pcdh19 knockout mouse models reproduce key features of human disorder
• Zebrafish models used for developmental studies
• Mechanistic understanding: protocadherins involved in synapse formation and neural circuit development

Investment & Strategic Analysis

Funding & M&A Activity

Valuation & Public Market Comparables (Updated March 2026)

Risk/Reward Assessment

Key Investment Themes (Updated 2026)

Regulatory Considerations for NDE Gene Therapy

FDA Accelerated Approval Pathway

The FDA's accelerated approval pathway is particularly relevant for NDE gene therapies given the high unmet need and limited treatment options. Key considerations include:

1. Orphan Drug Designation (ODD)

• All NDE programs qualify for ODD due to prevalence <200,000 in the US
• Benefits: 7 years market exclusivity, tax credits, waiver of user fees
• Required: Demonstrated scientific rationale and patient community support

• Companies developing therapies for rare pediatric diseases may receive a PRV
• PRVs can be sold or used for priority review of other products (valuable: $100M+)
• Most NDE gene therapy programs should qualify

• Biomarkers as surrogate endpoints: SCN1A expression in CSF (STK-001), UBE3A reactivation markers
• Seizure frequency reduction: >50% reduction considered clinically meaningful
• EEG normalization: Quantitative EEG improvements as endpoint
• Bayley-3 developmental scores: For pediatric populations

• STK-001 (Dravet) has received BTD due to substantial improvement over existing therapy
• Provides intensive FDA guidance and rolling review opportunities

Regulatory Challenges and Strategies

International Regulatory Landscape

Real-World Evidence (RWE) & Post-Marketing Frameworks

Why RWE Matters for NDE Gene Therapy

RWE Data Collection Strategies

1. Disease Registries

• Dravet Syndrome Registry (Taysha/UCB funded): Longitudinal data on 500+ patients
• Angelman Syndrome Foundation Registry: Natural history, treatment outcomes
• CDKL5 Disorder Registry: RDCRN supported

• seizure diaries (daily recording)
• Quality of life measures (PedsQL, EQ-5D-Y)
• Caregiver burden assessments (Zarit Burden Interview)
• Developmental assessments (Vineland-3, Bayley-3)

• Wearable seizure detection (Empatica, UNEEG)
• Continuous EEG monitoring
• Activity monitoring devices

Post-Marketing Safety Monitoring

Regulatory Expectations for RWE

• FDA 21st Century Cures Act: RWE can support label expansions
• EU EU4Health: Real-world data for orphan drugs
• Label expansion: Additional indications, dosage adjustments
• Reimbursement: RWE increasingly required by payers

Key Open Questions (Updated)

Clinical Trial Design Deep Dive

> Note: Dedicated clinical trial pages have been created for key programs. See:
> - [STK-001 (Stoke Therapeutics) — Dravet Phase 1/2 Trial](/clinical-trials/stk001-dravet-syndrome-phase-1-2)
> - [ETX101 (Encoded Therapeutics) — Dravet Gene Activation Therapy](/clinical-trials/etx101-encoded-therapeutics-dravet-syndrome)
> - [GTX-102 (GeneTx/Ultragenyx) — Angelman Phase 1/2 Trial](/clinical-trials/gtx102-angelman-syndrome-phase-1-2)
> - [Vigonvita CDKL5 Deficiency — Preclinical Program](/clinical-trials/vigonvita-cdkl5-deficiency-preclinical)
> - [STXBP1 Encephalopathy — Preclinical Program](/clinical-trials/stxbp1-encephalopathy-preclinical-program)
> - [KCNQ2 Encephalopathy — Gene Therapy Preclinical Programs](/clinical-trials/kcnq2-encephalopathy-preclinical)
> - [PCDH19 Epilepsy — Preclinical Program](/clinical-trials/pcdh19-epilepsy-preclinical-program)
> - [Roche/Neurocrine SCN1A AAV Gene Therapy — Dravet Syndrome](/clinical-trials/roche-neurocrine-scn1a-aav-dravet-syndrome)

Dravet Syndrome (SCN1A) — Clinical Trials

STK-001 (Stoke Therapeutics) — Phase 1/2 (NCT04414332)

Trial Design:

• Population: Patients ages 2-18 with genetically confirmed Dravet syndrome
• Dosing: Single intrathecal administration with optional retreatment
• Dose escalation: Multiple cohorts (10mg, 20mg, 30mg, 50mg)
• Duration: 5-year open-label follow-up

• Primary: Safety and tolerability
• Secondary: Seizure frequency reduction (diary), CGI-C (Clinical Global Impression of Change), Vineland-3 adaptive behavior
• Exploratory: SCN1A expression in CSF (biomarker), EEG changes

• >50% seizure reduction in >50% of responders at highest dose cohort (30mg, 50mg)
• Generally well-tolerated with manageable CSF abnormalities
• Biomarker data showing dose-dependent Nav1.1 expression in CSF
• Phase 2 (BEACON study, NCT05482706) enrollment completed Q4 2024, primary endpoint at 12 weeks
• FDA Breakthrough Therapy Designation granted Q1 2025 for STK-001
• Phase 2 data expected Q2-Q3 2026 — pivotal for BLA submission timing

ETX101 (Encoded Therapeutics) — Phase 1

Approach: AAV9-delivered CRISPR-activator (CRISPRa) targeting SCN1A promoter Delivery: Intra-cisterna magna (ICM) Status: Phase 1 clinical trial initiated Q1 2026 (first patient dosed)

Trial Design Considerations:

• Target: Pediatric patients (ages 2-8) — early intervention before severe developmental regression
• Primary endpoint: Seizure frequency reduction at 12 months
• Key biomarker: SCN1A mRNA expression in iPSC-derived neurons
• Phase 1/2 study (LAYLA) expected to enroll ~60 patients across dose escalation and expansion phases

Angelman Syndrome — Clinical Trials

GTX-102 (GeneTx/Ultragenyx) — Phase 1/2 (NCT04259281)

Trial Design:

• Population: Ages 4-17 with genetically confirmed Angelman syndrome
• Dosing: Intravenous infusion every 4 weeks for 12 weeks, then every 8 weeks
• Dose escalation: Multiple dose levels

• Primary: Safety and tolerability
• Secondary: Bayley-3 cognitive scores, EEG normalization, ABC-C (Aberrant Behavior Checklist-Community)
• Exploratory: UBE3A expression in skin biopsy

• Phase 1/2 (KIK-AS) data published showing dose-dependent UBE3A reactivation in CSF
• Phase 2 (KIK-AS-02) enrollment completed with 70+ patients (ages 4-17)
• Phase 2 data readout Q4 2025: statistically significant improvements in Bayley-3 cognitive scores at highest dose (12mg)
• EEG normalization observed in 40%+ of patients at higher dose levels
• Generally well-tolerated with transient injection site reactions
• BLA submission expected Q3-Q4 2026 based on Phase 2 results
• FDA Rare Pediatric Disease Priority Review Voucher (PRV) anticipated

KCNQ2 Encephalopathy — Trial Landscape

Current Status: No active clinical trials for gene therapy as of 2025

• Academic groups at CHOP and UC Davis in preclinical development
• Natural history studies ongoing to establish endpoints
• See dedicated page: [KCNQ2 Encephalopathy — Gene Therapy Preclinical Programs](/clinical-trials/kcnq2-encephalopathy-preclinical)

Academic Preclinical Programs — KCNQ2

Challenges for KCNQ2 gene therapy:

• Phenotypic variability: KCNQ2 mutations cause both gain-of-function and loss-of-function phenotypes
• Timing: Critical window during early brain development
• Target cell type: Need to target cortical pyramidal neurons

CDKL5 Deficiency — Trial Landscape

Current Status: No active clinical trials yet; Vigonvita program in IND-enabling studies

• See dedicated page: [Vigonvita CDKL5 Deficiency — Preclinical Program](/clinical-trials/vigonvita-cdkl5-deficiency-preclinical)
• Vigonvita Therapeutics AAV-CDKL5 program advancing toward IND
• Natural history studies ongoing at multiple centers

Academic Preclinical Programs — CDKL5

Challenges for CDKL5 gene therapy:

• Gene size: CDKL5 coding sequence fits within AAV capacity (~1.3kb)
• X-linked inheritance: Requires consideration for female carriers
• Therapeutic window: Early intervention critical for developmental rescue

Extended Preclinical Pipeline

Overview

SCN1A Preclinical Pipeline

UBE3A Preclinical Pipeline

KCNQ2 Preclinical Pipeline

CDKL5 Preclinical Pipeline

STXBP1 Preclinical Pipeline

GABRB3 Preclinical Pipeline

PCDH19 Preclinical Pipeline

Key Open Questions in Preclinical Pipeline

Manufacturing & CMC Considerations

AAV Production Platforms

Key CMC Challenges for NDE Programs

Cost Considerations

Manufacturing Capacity Constraints

• Current global capacity: Limited — major CDMOs have 2-3 year backlogs
• Key players: Thermo Fisher, Catalent, Cobra, UniQure
• Risk: Capacity constraints could delay clinical timelines

Patient Advocacy & Foundation Landscape

Key Organizations

Natural History Studies

Intranasal Delivery for NDE Gene Therapy

Overview

Mechanism

Advantages for NDE Applications

Technical Considerations

Delivery Efficiency

NDE-Specific Applications

Dravet Syndrome (SCN1A)

• Target: Olfactory bulb and limbic system
• Challenge: Limited cortical coverage
• Potential: Could be combined with FUS for broader distribution

• Target: Olfactory cortex and broader CNS
• Challenge: Whole-brain coverage needed

• Similar challenges as other NDEs
• Potential for early intervention before symptom onset

Companies and Programs

Comparison: Intranasal vs. Other Delivery Routes

Key Publications

Biomarker Development for NDE Gene Therapy

Why Biomarkers Matter for NDE Programs

Biomarkers serve multiple critical functions in NDE gene therapy development:

Biomarker Categories for NDE Gene Therapy

1. Genetic Biomarkers

2. Expression Biomarkers (Pharmacodynamic)

3. CSF Biomarkers

4. Electrophysiological Biomarkers

5. Imaging Biomarkers

Biomarker Validation Challenges

Regulatory Perspective on Biomarkers

• Surrogate endpoints: FDA willing to consider biomarker-based accelerated approval if "reasonably likely to predict clinical benefit"
• Qualification pathway: Biomarker Qualification Program (BQP) available for novel biomarkers
• Context of use: Each biomarker must be qualified for specific regulatory purpose
• Historical precedent: NfL as biomarker validated in multiple neurodegenerative diseases

Biomarker-Driven Development Strategies

Key Companies and Biomarker Programs

Future Directions

Clinical Endpoint Strategies for NDE Gene Therapy

Overview

Primary Endpoint Categories

1. Seizure-Based Endpoints

Key Consideration: Seizure diaries are caregiver-reported and may have gaps. Continuous EEG provides objective verification but is resource-intensive.

2. Developmental/Functional Endpoints

Key Consideration: NDE patients often have baseline deficits. Endpoint must be change from baseline, not absolute score.

3. Quality of Life / Functional Outcomes

4. Electrophysiological Endpoints

Regulatory Considerations

FDA Guidance for Rare Disease Trials

European EMA Perspective

• PRIME designation: Early engagement on trial design
• Adaptive pathways: Conditional approval based on early data
• Pediatric investigation plans: Required for all programs

Endpoint Selection by Disease

Dravet Syndrome (SCN1A)

Angelman Syndrome (UBE3A)

KCNQ2 Encephalopathy

Challenges in NDE Endpoint Assessment

Innovative Endpoint Approaches

Key Regulatory Precedents

Reimbursement and Health Economics Framework

Value Assessment for NDE Gene Therapies

The high upfront cost of gene therapies ($1-3M for one-time treatments) requires comprehensive value assessment frameworks that consider:

Clinical Value Components: Economic Value Components:

• Direct medical costs: Reduced hospitalizations, emergency visits, medication use
• Indirect costs: Lost caregiver earnings, educational interventions
• Lifetime cost savings: Avoided institutional care, long-term support services
• Productivity gains: Potential for eventual employment in mild cases

Pricing Models and Considerations

Historical Precedents: NDE-Specific Pricing Considerations:

• Single administration vs. lifetime of chronic therapies (ASMs, devices)
• Early intervention preventing irreversible damage justifies premium pricing
• Rare disease premiums under orphan drug legislation
• Performance-based arrangements with outcomes guarantees

Payer Engagement Strategies

Evidence Requirements:

Access Framework:

• Early access programs: Managed entry agreements in specific markets
• Outcomes-based contracting: Payment tied to achieved results
• Annuity models: Spread payments over time
• Orphan drug incentives: Utilize rare disease pathways (UK, EU)

Regional Reimbursement Landscape

United States:

• Private insurers: Increasingly covering gene therapies with prior authorization
• Medicare: Limited coverage for pediatric rare diseases
• Medicaid: State-by-state variation, some have gene therapy specific policies

• England (NICE): Requires QALY < £300,000; may require managed access
• Germany (IQWiG): Early benefit assessment required
• France: ASMR rating determines pricing
• Italy: Regional negotiation, AIFA monitoring

• Japan: Covers with specific conditions under advanced medical care
• Australia: Life-saving therapies at PBS with managed entry

Patient Assistance Programs

Most gene therapy developers offer:

• Co-pay assistance: Reduce patient out-of-pocket costs
• Travel support: Assist with treatment center access
• Navigators: Help families understand coverage options
• Charitable foundations: Partner with patient organizations for support

Long-Term Safety Monitoring & Pharmacovigilance for NDE Gene Therapy

Overview

Gene therapies for neurodevelopmental epilepsies require comprehensive long-term safety monitoring given their potential for decades of expression in pediatric patients. Unlike small molecule drugs that are cleared within hours to days, AAV-mediated gene therapy can result in persistent transgene expression for years to decades, necessitating unique safety surveillance approaches.

Key Safety Considerations for NDE Gene Therapies

1. Vector-Related Safety Concerns

2. Transgene-Specific Safety Concerns

3. Delivery-Related Safety Concerns

Pharmacovigilance Framework for NDE Gene Therapies

Post-Approval Surveillance Requirements

1. Long-Term Registry Studies

• Duration: Minimum 15-20 years for pediatric gene therapies
• Enrollment: All treated patients (post-approval commitment)
• Data collection:
• Annual neurological examinations
• Developmental milestone tracking
• Seizure diaries and EEG monitoring
• Quality of life assessments
• Adverse event reporting
• Death and serious adverse event reporting

3. Required Pharmacovigilance Activities

• Routine safety updates: Quarterly DSUR (Development Safety Update Reports)
• Periodic safety reviews: Annual benefit-risk assessment
• Signal detection: Continuous monitoring of adverse event databases
• Accelerated reporting: 15-day expedited reporting for serious unexpected events
• Risk management plans: Mandatory RMP with mitigation strategies

Special Populations Monitoring

Pediatric-Specific Considerations

• Developmental monitoring: IQ/DQ assessments at baseline, 1, 3, 5, 10, 15 years
• Growth parameters: Height, weight, head circumference trajectories
• Endocrine function: Growth hormone, thyroid, puberty progression
• Fertility: Long-term reproductive health assessment

Pregnancy Considerations

• Treated patients reaching childbearing age: Reproductive health counseling
• Pregnancy registry: Separate registry for patients who become pregnant post-treatment
• Lactation: Guidance on breastfeeding with potential vector excretion

Adverse Event Management

Expected Adverse Events by Frequency

Management Algorithms

Cytokine Release Syndrome (CRS) Management:

Liver Enzyme Elevation Management:

Risk Minimization Strategies

Pre-Treatment Risk Mitigation

• Pre-existing antibody screening: Test for neutralizing antibodies to AAV serotype
• Genetic testing confirmation: Verify pathogenic variant before treatment
• Immunomodulation: Pre-treatment with rituximab/rapamycin in high-risk patients

Post-Treatment Risk Mitigation

• Steroid cover: Short course of corticosteroids post-dosing
• Vaccination planning: Complete vaccinations before treatment, avoid live vaccines
• Infection prophylaxis: Consider prophylactic antivirals in first months

Global Regulatory Requirements

Long-Term Outcome Framework

Core Outcome Measures for NDE Gene Therapy

Surrogate Endpoints for Long-Term Monitoring

• Biomarker endpoints: Transgene expression levels (where measurable)
• Electrophysiological: EEG normalization patterns
• Imaging: MRI changes, brain volume trajectories
• Functional: Milestone achievement rates

Cost Considerations for Long-Term Monitoring

Industry Best Practices

Successful long-term monitoring programs:

• Stoke Therapeutics: 15-year follow-up protocol for STK-001
• AveXis/S Novartis: Zolgensma long-term registry (15 years)
• Bluebird Bio: Gene therapy long-term monitoring (20 years)

Competitive Timeline & Milestone Outlook (Updated 2026-03)

As of March 2026, several programs have reached key inflection points. This section tracks the competitive landscape with updated timelines reflecting current development status.

Updated Competitive Timeline

Key Milestone Events to Watch (2026)

Pediatric Pharmacokinetics & Dosing Considerations for NDE Gene Therapy

Overview

Age-Specific Considerations

Neonatal (0-1 year)

Infant (1-2 years)

• Critical window for intervention before major developmental regression
• Brain growth rapid — dose may need adjustment based on brain volume
• CSF dynamics more similar to toddler/child populations
• Optimal timing for gene therapy intervention under active investigation

Toddler/Child (2-12 years)

• Most common age for diagnosis and intervention
• Brain volume approaches 80-90% of adult by age 8
• Standard pediatric dosing principles apply (mg/kg or mg/m²)
• Long-term follow-up critical — expression may last for years

Dosing Strategies

Weight-Based Dosing

Route-Specific Adjustments

Pharmacokinetic Considerations

Vector Distribution

Clearance Mechanisms

• AAV clearance: Primarily through liver/reticuloendothelial system
• Transgene clearance: Not applicable — DNA persists in neurons
• Immune clearance: Anti-capsid antibodies may reduce re-dosing potential

Clinical Trial Dosing Considerations

Dose Selection for Pediatric Trials

Historical Precedents from Other Pediatric Gene Therapies

Key Open Questions in Pediatric PK

Digital Health & Remote Monitoring for NDE Gene Therapy Trials

Overview

Key Technologies

Wearable Seizure Detection Devices

Digital Biomarkers for NDE

Implementation in Gene Therapy Trials

Pre-Treatment Baseline

During Treatment/Follow-Up

Hybrid Endpoint Approaches

Regulatory Considerations

FDA Digital Health Guidance

• Software as Medical Device (SaMD): Classification depends on intended use
• Digital Health Innovation Action Plan: Supports innovation in digital endpoints
• Real-World Evidence: Digital data can supplement clinical trial data

Validation Requirements

Companies & Programs Using Digital Endpoints

Advantages for NDE Gene Therapy Trials

Challenges & Limitations

Future Directions

Global Access & Compassionate Use Pathways for NDE Gene Therapies

Overview

Compassionate Use Programs

US — Expanded Access (EA)

• Mechanism: FDA allows investigational products for patients with serious conditions
• Requirements: No comparable therapy, physician request, IRB approval
• Timeline: 30-60 days for approval
• Examples: Stoke has provided early access to STK-001 for certain patients

EU — Compassionate Use

• Mechanism: EMA guidelines for unapproved therapies
• Country-specific: Each member state has own procedures
• Key countries: Germany (most active), UK, France
• Timeline: Varies by country (2-6 months typical)

UK — MHRA Routes

• Early Access to Medicines Scheme (EAMS): Promising innovative medicines
• Specials license: Unlicensed medicines for individual patients
• Innovation passport: For transformative therapies

Regional Approval Strategies

US FDA

EMA

Japan — PMDA

• Sakigake designation: Fast-track for innovative therapies
• Conditional approval: For seriously unmet diseases
• Timeline: Similar to FDA/EMA

Global Pricing & Access Considerations

Patient Assistance Programs

Manufacturer Programs

• Free drug programs: For uninsured/underinsured during approval gap
• Co-pay assistance: Reduce out-of-pocket costs
• Travel support: For trial visits
• Case management: Navigation support

Foundation Partnerships

• Dravet Syndrome Foundation: Patient navigation, advocacy
• Angelman Syndrome Foundation: Family support, research funding
• Cute Syndrome Foundation: CDKL5 research, family support
• SLC6A1 Connect: Patient registry, research funding
• PCDH19 Alliance: Patient registry, research
• KCNQ2 Cure Foundation: Research funding, family support

Access Equity Considerations

Preclinical Translation Challenges & Model Systems

Overview

Model Systems Used in NDE Gene Therapy Development

1. Mouse Models

Key Considerations for Mouse Models:

• Blood-brain barrier maturity differs from human infants
• Immune response to AAV may not predict human reactions
• Seizure behavior assessment is subjective
• Developmental timeline compressed (mouse vs human)

2. Induced Pluripotent Stem Cell (iPSC) Models

Limitations:

• Immature neuronal phenotype (fetal-like)
• Lack of mature circuit connectivity
• Variable differentiation efficiency
• Cost-prohibitive for large-scale screens

3. Large Animal Models (Porcine, Non-Human Primate)

Value for NDE Programs:

• Better prediction of biodistribution
• Translation of dosing regimens
• Safety assessment for delivery methods
• Immune response prediction

Key Translation Gaps

Strategies to Improve Translation

Regulatory Perspective on Preclinical Data

FDA and EMA require:

• Efficacy: Demonstration in relevant animal model
• Safety: Toxicity studies in two species (rodent + non-rodent)
• Biodistribution: Vector distribution studies
• GM biology: Integration analysis, off-target effects (for gene editing)

Key Open Questions in Translation

Natural History Studies for NDE

Understanding the natural history of neurodevelopmental epilepsies is critical for clinical trial design, endpoint selection, and regulatory approval. Natural history studies establish baseline disease progression, identify meaningful clinical endpoints, and provide comparator data for treatment effects.

Overview

NDEs are characterized by early-onset seizures, developmental regression, and heterogeneous phenotypes. Natural history studies help characterize:

• Seizure trajectory: Age of onset, seizure types, frequency over time
• Developmental outcomes: Cognitive and motor development milestones
• Biomarker evolution: EEG patterns, genetic modifiers, protein biomarkers
• Quality of life: Family burden, functional abilities, behavioral comorbidities

Disease-Specific Natural History

Dravet Syndrome (SCN1A)

Key endpoints being validated:

• Seizure frequency (daily diaries)
• Vineland-3 adaptive behavior scale
• CGI-C (Clinical Global Impression of Change)
• Quality of life measures (QOLCE-55)

Angelman Syndrome (UBE3A)

Key endpoints being validated:

• Bayley-III developmental assessment
• Communication function (MACI scale)
• CGI-C in non-verbal domains
• Sleep quality measures

CDKL5 Deficiency Disorder

Key endpoints being validated:

• Motor function (GMFCS)
• Seizure frequency/diary
• Visual function (cortical blindness)
• Caregiver burden measures

KCNQ2 Encephalopathy

Key endpoints being validated:

• Early developmental assessment (INFANT-m)
• EEG normalization as biomarker
• Seizure freedom duration

Regulatory Considerations

• FDA draft guidance (2023): Emphasizes natural history as external control for rare disease trials
• Rare pediatric disease PRV: 6-month priority review voucher available
• Accelerated approval pathway: Requires surrogate endpoint reasonably likely to predict clinical benefit
• Natural history as comparator: Must match baseline characteristics, adjust for confounders

Future Directions

• Multi-center registries: Consolidate data across RDCRN, industry, academic
• Standardized endpoints: Adopt consensus Core Outcome Sets
• Biomarker validation: CSF, EEG, genetic modifiers as predictive markers
• Long-term follow-up: 10+ year registries needed for durability assessment

Combination Approaches with Anti-Seizure Medications

Overview

Current Standard of Care ASMs

Gene Therapy + ASM Combination Strategies

Pre-Treatment (Prior to Gene Therapy)

• ASM optimization: Stabilize patients on minimal effective ASM regimen before gene therapy
• Seizure freedom: Aim for seizure freedom period pre-treatment to establish baseline
• Washout considerations: Some ASMs may interfere with transduction or expression

During Expression Period (Weeks-Months Post-Dosing)

• Adjunctive use: Continue ASMs while waiting for gene therapy expression
• Taper planning: Develop ASM taper protocols based on expression milestones
• Rescue medications: Maintain rescue diazepam protocols for breakthrough seizures

Long-Term (Post-Expression)

• ASM discontinuation: Gradual taper if sustained seizure freedom achieved
• Rescue protocols: Maintain rescue plans for seizure clusters
• Breakthrough management: Plan for ASM re-initiation if needed

Potential Drug-Drug Interactions

Clinical Trial Design Considerations

Pediatric Considerations

Combination Future Directions

Cross-Links

• [AAV Gene Therapy for Neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration)
• [AAV Gene Therapy for Parkinson's](/therapeutics/aav-gene-therapy-parkinsons)
• [AAV Vectors](/technologies/aav-vectors)
• [Gene Therapy Overview](/technologies/gene-therapy)
• [Antisense Oligonucleotide Therapy](/technologies/antisense-oligonucleotides)
• [AAV Investment Landscape](/investment/aav-gene-therapy)
• [Viral Vector Delivery](/investment/viral-vector-delivery-gene-therapy)
• [Dravet Syndrome Foundation](/organizations/dravet-syndrome-foundation)
• [Angelman Syndrome Foundation](/organizations/angelman-syndrome-foundation)
• [Cute Syndrome Foundation](/organizations/cute-syndrome-foundation)
• [KCNQ2 Cure Foundation](/organizations/kcnq2-cure-foundation)
• [STXBP1 Foundation](/organizations/stxbp1-foundation)
• [PCDH19 Alliance](/organizations/pcdh19-alliance)
• [SLC6A1 Connect](/organizations/slc6a1-connect)
• [Ring14 USA](/organizations/ring14-usa)
• [Lipid Nanoparticle CNS Delivery](/technologies/lipid-nanoparticle-cns-delivery)
• [Exosome-Based CNS Delivery](/technologies/exosome-cns-delivery)
• [Base and Prime Editing for NDE](/technologies/base-prime-editing-neurodevelopmental-epilepsy)
• [CRISPR Gene Editing](/technologies/crispr-gene-editing)

See Also

Related Hypotheses:

• [Purinergic Signaling Polarization Control](/hypotheses/h-0758b337)
• [Mechanosensitive Ion Channel Reprogramming](/hypotheses/h-db6aa4b1)
• [Lipid Droplet Dynamics as Phenotype Switches](/hypotheses/h-7d4a24d3)

• [AAV-LRRK2 Gene Therapy IND-Enabling Study Design](/experiment/exp-wiki-experiments-lrrk2-aav-ind-enabling-study)
• [AAV-LRRK2 IND-Enabling Study Design](/experiment/exp-wiki-experiments-aav-lrrk2-ind-enabling-studies)
• [AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy](/experiment/exp-wiki-experiments-aaav-serotype-lrrk2-gene-therapy)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
• [Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PIEZO1 and KCNK2
• [Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DGAT1 and SOAT1
• [Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery](/hypothesis/h-d78123d1) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: RAB27A/LAMP2B
• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1

Related Analyses:

• [CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;